Flightpath's R&D team is building a comprehensive array of technologies to tackle the planet’s most biologically sophisticated pathogens.
Human Therapeutic Development Programs
| Product Name | Program | Primary Pathogen | Discovery | Preclinical | Clinical | Marketed | Development Partner |
|---|---|---|---|---|---|---|---|
| FP-100 | acute Lyme borreliosis | B. burgdorferi | internal | ||||
|
Description: FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
|||||||
| FP-101 | persistent Lyme disease | B. burgdorferi | internal | ||||
|
Description: FP-101 is a previously FDA-approved IV antibiotic that has been transitioned into a targeted-delivery oral therapeutic for the treatment of persistent Lyme infections while reducing impact on the gut microbiome.
Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
|||||||
| FP-100 | syphilis, yaws, periodontal disease, leptospirosis | T. pallidum, T. denticola, Leptospira |
internal | ||||
|
Description: FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
|||||||
Microbiome Discovery Program
| Product Name | Program | Primary Pathogen | Discovery | Preclinical | Clinical | Marketed | Development Partner |
|---|---|---|---|---|---|---|---|
| Microbiome Signature | Chronic Lyme disease diagnostic | TBD - proprietary | external - partnered | ||||
|
Description: Both the underlying mechanism responsible for chronic Lyme disease symptoms, as well as a reliable diagnostic tool, has remained elusive. Analysis of data from a rigorously curated cohort of chronic Lyme disease patients revealed a gut microbiome signature distinct from that of healthy control subjects, as well as from that of intensive care unit (ICU) patients, which presents a potential, novel diagnostic tool for chronic Lyme disease. Ownership: Global development and commercialization rights have been partnered with a scaled diagnostic manufacturing partner. |
|||||||
| Microbiome Consortia | Chronic Lyme therapeutic | TBD - proprietary | internal | ||||
|
Description: A therapeutic bacterial probiotic consortia program to repair dysbiosis in the microbiomes of chronic Lyme disease patients Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
|||||||
Flightpath is seeking partners interested in developing agricultural and animal health applications.
Contact Us for more information